Bomyntra (Denosumab-Bnht) for Multiple Myeloma

Bomyntra (denosumab-bnht) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to prevent bone problems, also called skeletal-related events, in people with multiple myeloma.

How Bomyntra Works and How It’s Taken

Bomyntra is a type of medicine called a RANK ligand (RANKL) inhibitor. It works by blocking RANKL, a protein that helps activate cells that break down bone.

In multiple myeloma, this may help lower bone damage and other bone problems. These include broken bones, the need for radiation or surgery to bone, and spinal cord compression.

Doctors prescribe Bomyntra when they want to help prevent skeletal-related events, which are serious bone problems linked to multiple myeloma.

Bomyntra is a biosimilar of Xgeva. This means it is made from living cells and is designed to work like the original medicine. The FDA requires biosimilars to have no meaningful differences in safety or how well they work.

Bomyntra is given as an injection under the skin by a healthcare provider. It is usually given every four weeks. It may be given in the upper arm, upper thigh, or abdomen.

Typical Dosing for Multiple Myeloma

The recommended dose of Bomyntra for multiple myeloma is 120 milligrams injected under the skin every four weeks.

This information is based on the prescribing information, but your healthcare provider may tailor your treatment plan. Always follow their guidance.

Bomyntra Side Effects

In clinical trials of Bomyntra for preventing skeletal-related events in people with multiple myeloma, the most common side effects occurred in about 11 percent to 34 percent of people. These include:

Diarrhea
Nausea
Anemia (low red blood cell count)
Back pain
Thrombocytopenia (low platelet count)
Peripheral edema (swelling, usually in the legs, ankles, or feet)
Hypocalcemia (low calcium levels)
Upper respiratory tract infection, such as a cold
Rash
Headache

Serious Side Effects and Warnings

Bomyntra can cause serious side effects that may require immediate medical attention. These include:

Severe allergic reactions — Hypersensitivity, including anaphylaxis, can cause trouble breathing, swelling, hives, or low blood pressure.
Severe hypocalcemia — Dangerously low calcium levels can cause symptoms and have been fatal in some cases.
Osteonecrosis of the jaw (ONJ) — Jawbone damage can cause jaw pain, tooth or gum infections, or sores that do not heal.
Atypical femoral fracture — An unusual thigh bone fracture may cause new or unusual thigh, hip, or groin pain.
Multiple vertebral fractures after stopping treatment — Broken bones in the spine have been reported after denosumab products were discontinued.
Embryo-fetal toxicity — Bomyntra can harm your baby if used during pregnancy.

Get medical help right away if you think you are having a serious reaction.

How To Save on Bomyntra

Fresenius Kabi USA, the manufacturer of Bomyntra, offers the KabiCare Patient Support Program. The KabiCare Patient Support Program also offers enrollment assistance, financial support, insurance support, and clinical support throughout treatment.

To learn more, visit the Bomyntra support resources page or call 833-522-4227.

What To Know Before Taking Bomyntra

Before starting Bomyntra, your doctor will check your calcium level. Any low calcium must be corrected before treatment starts. Your doctor may also recommend calcium and vitamin D to help treat or prevent low calcium levels.

Tell your doctor if you have any allergies to denosumab products. Do not take Bomyntra if you have had a serious allergic reaction to Bomyntra or any of its ingredients.

Tell your doctor about all medications you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements.

Tell your doctor if you have kidney problems or are on dialysis. You may have a higher risk of low calcium.

Your doctor should check your mouth and teeth before you start Bomyntra. Tell your dentist that you are taking Bomyntra.

Keep good oral hygiene and avoid invasive dental procedures during treatment when possible.

Bomyntra is also FDA-approved to treat adults and skeletally mature adolescents with a giant cell tumor of bone that cannot be removed by surgery or where surgery may cause severe problems. It is also approved to treat hypercalcemia of malignancy that did not respond to bisphosphonate therapy.

If you are pregnant, are planning to become pregnant, or are breastfeeding while taking Bomyntra, talk with your doctor about the risks and benefits.

Bomyntra can harm your baby if used during pregnancy. If you can become pregnant, your doctor should verify that you are not pregnant before starting Bomyntra.

You should use effective birth control during treatment and for at least five months after your last dose.

Community FAQs

These answers are fact-checked by our editorial staff.

How effective is Bomyntra?

In a study of 1,718 people with newly diagnosed multiple myeloma and bone lesions, denosumab worked about as well as another bone medicine called zoledronic acid at delaying the first skeletal-related event. A skeletal-related event is a serious bone problem. This can include a broken bone, radiation treatment to bone, surgery to bone, or spinal cord compression.

Overall survival was also similar between the denosumab and zoledronic acid groups.

In people with newly diagnosed multiple myeloma, denosumab lowered uNTx/Cr by about 75 percent by week 5. uNTx/Cr is a marker of bone turnover, which means how quickly bone is being broken down and rebuilt. These reductions stayed at about 74 percent to 79 percent from weeks 9 to 49 when treatment was given every four weeks.

How long does Bomyntra take to work for multiple myeloma?

In a clinical study of people with newly diagnosed multiple myeloma, denosumab lowered levels of uNTx/Cr by about 75 percent by week 5 when given every four weeks.

uNTx/Cr is a marker of bone turnover, which means it helps show how quickly bone is being broken down and rebuilt. Researchers used this marker to measure the effects of treatment on bone turnover.

The reductions in uNTx/Cr were maintained during continued treatment, with decreases of about 74 percent to 79 percent from weeks 9 to 49. The clinical study data does not show when individuals may notice a benefit from treatment.

What tests or monitoring are needed with Bomyntra for multiple myeloma?

Your doctor should check your calcium level before you start Bomyntra. Any low calcium must be corrected before treatment begins.

Calcium levels should be monitored during treatment, especially during the first weeks after starting Bomyntra. Your doctor may recommend calcium, magnesium, and vitamin D if needed.

People with severe kidney problems or who are on dialysis have a higher risk of low calcium levels. In these individuals, calcium levels and calcium and vitamin D intake should be monitored closely.

Your doctor should examine your mouth and teeth before you start treatment. Good oral hygiene is important during treatment with Bomyntra.

Tell your dentist that you are receiving Bomyntra. Avoid invasive dental procedures when possible during treatment.

Contact your doctor if you develop symptoms involving your mouth or jaw, such as jaw pain or slow healing after dental work.